International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 5, Issue 4 | Research Article | Open Access
Qasim Zia,*
Mubeen Shahid1, Syeda Ayesha Bukhari1, Ayesha Abbas2, Muhammad Usama Khalid3, Muhammad Zaki Ud Din4, Hajra Azmat5, Muhammad Sheraz6, Qasim Zia7*, Muhammad Salman Khan7
1Multan Medical & Dental College, Multan
2Bahawal Victoria Hospital, Bahawalpur
3,4,7Multan Medical & Dental College, Multan
5M. Islam Medical and Dental College, Gujranwala
6Nishtar Medical University, Multan
*Correspondence to: Qasim Zia,
Fulltext PDFObesity and type 2 diabetes mellitus (T2DM) are chronic metabolic disorders associated with increased cardiovascular morbidity and mortality. Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), have transformed metabolic disease management. Semaglutide has demonstrated robust efficacy in weight reduction and cardiovascular risk reduction, whereas tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1receptor agonist, has emerged as a potentially superior metabolic therapy. Methods: A systematic review and meta-analysis was conducted following PRISMA guidelines. PubMed, Embase, Cochrane Library, and Scopus were searched up to February 2026. Randomized controlled trials and comparative observational studies evaluating tirzepatide versus semaglutide were included. Outcomes included weight reduction, HbA1c reduction, cardiometabolic parameters, and adverse events. Results: Tirzepatide demonstrated significantly greater weight reduction compared to semaglutide (mean difference − 4.5% to − 5.2%) and superior HbA1c reduction.[1-3] Both agents improved lipid parameters and blood pressure. However, semaglutide demonstrated more robust evidence for cardiovascular event reduction in large outcome trials.[12-14] Gastrointestinal adverse effects were the most common in both groups with comparable discontinuation rates.[4-6] Conclusion: Tirzepatide provides superior metabolic efficacy, while semaglutide retains stronger cardiovascular outcome evidence. Therapeutic selection should be individualized based on patient comorbidities and clinical priorities.
Mubeen Shahid, Syeda Ayesha Bukhari, Ayesha Abbas, Muhammad Usama Khalid, Muhammad Zaki Ud Din, Hajra Azmat, Muhammad Sheraz, Qasim Zia, Muhammad Salman Khan. Beyond Weight Loss: Comparative Efficacy, Safety, and Cardiometabolic Effects of Tirzepatide versus Semaglutide — A Systematic Review and Meta-Analysis. Int Clinc Med Case Rep Jour. 2026;5(4):1-5.